| ［1］ |
Zhao ZT, Ji CM, Yu WJ, et al. Omalizumab for the treatment of chronic spontaneous urticaria: a meta⁃analysis of randomized clinical trials［J］. J Allergy Clin Immunol, 2016,137（6）:1742⁃1750. doi: 10.1016/j.jaci.2015.12.1342.
|
| ［2］ |
Chang TW, Chen C, Lin CJ, et al. The potential pharmacologic mechanisms of omalizumab in patients with chronic spontaneous urticaria［J］. J Allergy Clin Immunol, 2015,135（2）:337⁃342. doi: 10.1016/j.jaci.2014.04.036.
|
| ［3］ |
Maurer M, Bindslev⁃Jensen C, Gimenez⁃Arnau A, et al. Chronic idiopathic urticaria （CIU） is no longer idiopathic: time for an update［J］. Br J Dermatol, 2013,168（2）:455⁃456. doi: 10.1111/ j.1365⁃2133.2012.11171.x.
|
| ［4］ |
Dressler C, Rosumeck S, Werner RN, et al. Executive summary of the methods report for ′The EAACI/GA2 LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. The 2017 revision and update′［J］. Allergy, 2018,73（5）:1145⁃1146. doi: 10.1111/all.13414.
|
| ［5］ |
Kaplan A, Ferrer M, Bernstein JA, et al. Timing and duration of omalizumab response in patients with chronic idiopathic/spontaneous urticaria［J］. J Allergy Clin Immunol, 2016,137（2）:474⁃481. doi: 10.1016/j.jaci.2015.08.023.
|
| ［6］ |
Kaplan A, Ferrer M, Bernstein JA, et al. Timing and duration of omalizumab response in patients with chronic idiopathic/spontaneous urticaria［J］. J Allergy Clin Immunol, 2016,137（2）:474⁃481. doi: 10.1016/j.jaci.2015.08.023.
|
| ［7］ |
Asero R, Tedeschi A, Marzano AV, et al. Chronic urticaria: a focus on pathogenesis［J］. F1000Res, 2017,6:1095. doi: 10.12688/ f1000research.11546.1.
|
| ［8］ |
Saini SS. Chronic spontaneous urticaria: etiology and pathogenesis［J］. Immunol Allergy Clin North Am, 2014,34（1）:33⁃52. doi: 10.1016/j.iac.2013.09.012.
|
| ［9］ |
Kolkhir P, Church MK, Weller K, et al. Autoimmune chronic spontaneous urticaria: what we know and what we do not know［J］. J Allergy Clin Immunol, 2017,139（6）:1772⁃1781. doi: 10. 1016/j.jaci.2016.08.050.
|
| ［10］ |
Tedeschi A, Kolkhir P, Asero R, et al. Chronic urticaria and coagulation: pathophysiological and clinical aspects［J］. Allergy, 2014,69（6）:683⁃691. doi: 10.1111/all.12389.
|
| ［11］ |
Yanase Y, Takahagi S, Hide M. Chronic spontaneous urticaria and the extrinsic coagulation system［J］. Allergol Int, 2018,67（2）:191⁃194. doi: 10.1016/j.alit.2017.09.003.
|
| ［12］ |
Kaplan AP, Giménez⁃Arnau AM, Saini SS. Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria［J］. Allergy, 2017,72（4）:519⁃533. doi:10.1111/all.13083.
|
| ［13］ |
Serrano⁃Candelas E, Martinez⁃Aranguren R, Valero A, et al.Comparable actions of omalizumab on mast cells and basophils［J］. Clin Exp Allergy, 2016,46（1）:92⁃102. doi:10.1111/cea. 12668.
|
| ［14］ |
Lowe PJ, Renard D. Omalizumab decreases IgE production in patients with allergic （IgE⁃mediated） asthma; PKPD analysis of a biomarker, total IgE［J］. Br J Clin Pharmacol, 2011,72（2）:306⁃320. doi: 10.1111/j.1365⁃2125.2011.03962.x.
|
| ［15］ |
Metz M, Staubach P, Bauer A, et al. Clinical efficacy of omalizumab in chronic spontaneous urticaria is associated with a reduction of FcεRI⁃positive cells in the skin［J］. Theranostics, 2017,7（5）:1266⁃1276. doi: 10.7150/thno.18304.
|
| ［16］ |
Beck LA, Marcotte GV, MacGlashan D, et al. Omalizumab⁃induced reductions in mast cell Fc epsilon RI expression and function［J］. J Allergy Clin Immunol, 2004,114（3）:527⁃530. doi: 10.1016/j.jaci.2004.06.032.
|
| ［17］ |
Beck LA, Marcotte GV, MacGlashan D, et al. Omalizumab⁃induced reductions in mast cell Fc epsilon RI expression and function［J］. J Allergy Clin Immunol, 2004,114（3）:527⁃530.
|
| ［18］ |
Ertas R, Ozyurt K, Ozlu E, et al. Increased IgE levels are linked to faster relapse in patients with omalizumab⁃discontinued chronic spontaneous urticaria［J］. J Allergy Clin Immunol, 2017,140（6）:1749⁃1751. doi: 10.1016/j.jaci.2017.08. 007.
|
| ［19］ |
Gericke J, Metz M, Ohanyan T, et al. Serum autoreactivity predicts time to response to omalizumab therapy in chronic spontaneous urticaria［J］. J Allergy Clin Immunol, 2017,139（3）:1059⁃1061. doi: 10.1016/j.jaci.2016.07.047.
|
| ［20］ |
Deza G, Bertolín⁃Colilla M, Pujol RM, et al. Basophil FcεRI expression in chronic spontaneous urticaria: a potential immunological predictor of pesponse to omalizumab therapy［J］. Acta DermVenereol, 2017,97（6）:698⁃704. doi: 10.2340/000155 55⁃2654.
|
| ［21］ |
Palacios T, Stillman L, Borish L, et al. Lack of basophil CD203c⁃upregulating activity as an immunological marker to predict response to treatment with omalizumab in patients with symptomatic chronic urticaria［J］. J Allergy Clin Immunol Pract, 2016,4（3）:529⁃530. doi: 10.1016/j.jaip.2015.11.025.
|
| ［22］ |
Asero R. D⁃dimer: a biomarker for antihistamine⁃resistant chronic urticaria［J］. J Allergy Clin Immunol, 2013,132（4）:983⁃986. doi: 10.1016/j.jaci.2013.04.037.
|
| ［23］ |
Asero R, Marzano AV, Ferrucci S, et al. D⁃dimer plasma levels parallel the clinical response to omalizumab in patients with severe chronic spontaneous urticaria［J］. Int Arch Allergy Immunol, 2017,172（1）:40⁃44. doi: 10.1159/000453453.
|
